T-cadherin downregulation is associated with poorer prognoses in various carcinomas, such as lung, ovarian, cervical and prostate cancer, while in the majority of cancer cell lines, T-cadherin re-expression inhibits cell proliferation and invasiveness, increases susceptibility to apoptosis and reduces tumor growth in in vivo models. The gene discussed is CDH13; the disease is prostate cancer.